Your browser doesn't support javascript.
loading
Human embryonic stem cell-derived cardiomyocyte platform screens inhibitors of SARS-CoV-2 infection.
Williams, Thomas L; Colzani, Maria T; Macrae, Robyn G C; Robinson, Emma L; Bloor, Stuart; Greenwood, Edward J D; Zhan, Jun Ru; Strachan, Gregory; Kuc, Rhoda E; Nyimanu, Duuamene; Maguire, Janet J; Lehner, Paul J; Sinha, Sanjay; Davenport, Anthony P.
Afiliación
  • Williams TL; Experimental Medicine and Immunotherapeutics, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.
  • Colzani MT; Wellcome-MRC Cambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, UK.
  • Macrae RGC; Experimental Medicine and Immunotherapeutics, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.
  • Robinson EL; Wellcome-MRC Cambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, UK.
  • Bloor S; School of Medicine, Division of Cardiology, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA.
  • Greenwood EJD; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, UK.
  • Zhan JR; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, UK.
  • Strachan G; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, UK.
  • Kuc RE; Wellcome Trust-MRC Institute of Metabolic Science, Metabolic Research Laboratories, Addenbrooke's Biomedical Campus, Cambridge, UK.
  • Nyimanu D; Experimental Medicine and Immunotherapeutics, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.
  • Maguire JJ; Experimental Medicine and Immunotherapeutics, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.
  • Lehner PJ; Experimental Medicine and Immunotherapeutics, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.
  • Sinha S; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, UK.
  • Davenport AP; Wellcome-MRC Cambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, UK. ss661@cam.ac.uk.
Commun Biol ; 4(1): 926, 2021 07 29.
Article en En | MEDLINE | ID: mdl-34326460
ABSTRACT
Patients with cardiovascular comorbidities are more susceptible to severe infection with SARS-CoV-2, known to directly cause pathological damage to cardiovascular tissue. We outline a screening platform using human embryonic stem cell-derived cardiomyocytes, confirmed to express the protein machinery critical for SARS-CoV-2 infection, and a SARS-CoV-2 spike-pseudotyped virus system. The method has allowed us to identify benztropine and DX600 as novel inhibitors of SARS-CoV-2 infection in a clinically relevant stem cell-derived cardiomyocyte line. Discovery of new medicines will be critical for protecting the heart in patients with SARS-CoV-2, and for individuals where vaccination is contraindicated.
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Antivirales / Miocitos Cardíacos / Evaluación Preclínica de Medicamentos / Células Madre Embrionarias Humanas / SARS-CoV-2 Límite: Humans Idioma: En Revista: Commun Biol Año: 2021 Tipo del documento: Article País de afiliación: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Antivirales / Miocitos Cardíacos / Evaluación Preclínica de Medicamentos / Células Madre Embrionarias Humanas / SARS-CoV-2 Límite: Humans Idioma: En Revista: Commun Biol Año: 2021 Tipo del documento: Article País de afiliación: Reino Unido